EcoDrugPlus

Ptk6 Protein Tyrosine Kinase 6b

Ensembl ID : ENSOMYG00000002002
Gene Symbol: PTK6B
1 Cross references
159 Possible Orthologues:

Pim-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSOMYG00000040587
Gene Symbol: PIM1
1 Cross references
239 Possible Orthologues:

Pim-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSOMYG00000007231
Gene Symbol: PIM1
1 Cross references
240 Possible Orthologues:

Pim-3 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSOMYG00000040827
Gene Symbol: PIM3
1 Cross references
152 Possible Orthologues:

Proteasome Subunit Beta Type 2

Ensembl ID : ENSOMYG00000037332
Gene Symbol: PSB2
3 Cross references
213 Possible Orthologues:

Proteasome Subunit Beta Type 4

Ensembl ID : ENSOMYG00000027735
Gene Symbol: PSB4
2 Cross references
208 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSOMYG00000008329
Gene Symbol: ROCK2
1 Cross references
219 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSOMYG00000037255
Gene Symbol: ROCK2
1 Cross references
219 Possible Orthologues:

Rho-Associated, Coiled-Coil Containing Protein Kinase 1

Ensembl ID : ENSOMYG00000036817
Gene Symbol: ROCK1
1 Cross references
207 Possible Orthologues:

Sem1 26s Proteasome Subunit

Ensembl ID : ENSOMYG00000008161
Gene Symbol: SEM1
1 Cross references
150 Possible Orthologues:

Tek Tyrosine Kinase, Endothelial

Ensembl ID : ENSOMYG00000007424
Gene Symbol: TEK
1 Cross references
159 Possible Orthologues:

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSOMYG00000028692
Gene Symbol: UGCG
1 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).